Elias Dominique, Liberale Gabriel, Vernerey Déwi, Pocard Marc, Ducreux Michel, Boige Valérie, Malka David, Pignon Jean-Pierre, Lasser Philippe
Department of Surgical Oncology, Institut Gustave Roussy, Comprehensive Cancer Center, 39 Rue Camille Desmoulins, Villejuif Cédex, 94805, France.
Ann Surg Oncol. 2005 Nov;12(11):900-9. doi: 10.1245/ASO.2005.01.010. Epub 2005 Sep 26.
The presence of extrahepatic disease (EHD) is considered a contraindication to hepatectomy in patients with colorectal liver metastases. After resection, the prognosis is based more on the total number of resected metastases (located inside and outside the liver) than on the site of these metastases (only inside the liver or not).
A total of 308 patients with colorectal cancer underwent hepatectomy, and 84 (27%) also underwent resection of miscellaneous EHD. The study was a prospective data registration and retrospective analysis. When considering the total number of resected metastases, each liver metastasis and each EHD location was counted as one lesion. Univariate and multivariate analyses were performed.
The median follow-up was 99 months. The overall 5-year survival rate was 32%. In the multivariate analysis, the total number of metastases (inside or outside the liver) had a greater prognostic value than the criterion "presence or absence of EHD." Considering the total number of resected metastases (whatever their site), 5-year survival rates were 38% (SD: 4%) in the group with one to three metastases, 29% (SD: 5%) in patients with four to six metastases, and 18% (SD: 5%) in patients with more than six metastases (P = .002). A very simple prognostic score based on sex and the total number of metastases is proposed.
EHD, when resectable, is no longer a contraindication to hepatectomy. More importantly, the total number of the metastases, whatever their location, has a stronger prognostic effect than the site of these metastases.
肝外疾病(EHD)的存在被认为是结直肠癌肝转移患者行肝切除术的禁忌证。切除术后,预后更多地取决于切除的转移灶总数(位于肝内和肝外),而非这些转移灶的位置(仅在肝内或不在肝内)。
共有308例结直肠癌患者接受了肝切除术,其中84例(27%)还接受了其他肝外疾病的切除术。本研究为前瞻性数据登记和回顾性分析。在考虑切除的转移灶总数时,每个肝转移灶和每个肝外疾病部位都计为一个病灶。进行了单因素和多因素分析。
中位随访时间为99个月。总体5年生存率为32%。在多因素分析中,转移灶总数(肝内或肝外)比“是否存在肝外疾病”这一标准具有更大的预后价值。考虑切除的转移灶总数(无论其位置如何),转移灶为1至3个的组5年生存率为38%(标准差:4%),转移灶为4至6个的患者为29%(标准差:5%),转移灶超过6个的患者为18%(标准差:5%)(P = 0.002)。提出了一种基于性别和转移灶总数的非常简单的预后评分。
可切除的肝外疾病不再是肝切除术的禁忌证。更重要的是,转移灶总数,无论其位置如何,比这些转移灶的位置具有更强的预后影响。